摘要:
The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.
摘要:
The invention relates to special (methyl)acrylaic monomers and concerns more particularly an enhanced process for preparing solutions of alkylimiozolidone (meth)acrylates in water solutions of alkylimidazolidone (meth)acrylates in a light (meth)acrylate.
摘要:
Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.
摘要:
Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.
摘要:
A novel solventless process is described for the preparation of imidazole-2-thiones. The new solventless process tolerates a variety of bases as co-reactants which introduces feedstock flexibility into the process while the solventless feature renders the process more environmentally friendly by eliminating volatile organic solvents from the process, reducing energy consumption (associated with solvent recovery and/or recycling), and allows shorter reaction time and workup. Furthermore, the elimination of solvents enhances workplace safety by obviating the need for flammable and/or toxic solvents.
摘要:
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.
摘要:
In order to subject a cellulosic material such as insulating paper onto and into which transformer high-voltage insulating oil containing PCB has adhered and permeated to washing that removes the PCB etc. to an undetectable value, the cellulosic material to which PCB etc. has adhered is placed in DMI, sulfolane or other aprotic solvent containing an alkali such as caustic soda and stirred.
摘要:
A class of imidazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1## wherein R.sup.1 -R.sup.6 are as described in the specification; or a pharmaceutically-acceptable salt thereof.
摘要:
2.2. 1,3-imidazolidine-4-ones having the General Formula: ##STR1## are obtained in a pure form especially by means of precipitation, in which production an optically active acid can be used at 0.5-0.8 eq. for the separation of racemates. The non-desired enantiomer can be racemized in an inert solvent and the cyclization to imidazolidinone can take place by means of the optically active acid, whereupon the separation of racemates takes place directly thereafter. 1,3-imidazolidine-4-ones are valuable educts for the preparation of branched or unbranched, proteinogenic or non-proteinogenic .alpha.-amino acids by means of diastereoselective alkylation and subsequent ring splitting.
摘要:
The invention relates to cyclic urea derivatives of general formula ##STR1## wherein R.sub.a, R.sub.b, X and Y are as defined herein, pharmaceutical compositions containing the derivatives and processes for preparing them.